Cingulate to Participate in Benzinga All Live Access Event
August 15, 2022 18:34 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
August 11, 2022 06:45 ET
|
Cingulate Inc.
$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage...
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
June 23, 2022 07:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
June 02, 2022 14:40 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
May 24, 2022 06:45 ET
|
Cingulate Inc.
Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using...
Cingulate to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 17:20 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
May 12, 2022 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Presents at NobleCon18
April 26, 2022 12:27 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug...
NetworkNewsWire Announces Publication on Innovative Advancements Merging Cannabis and Drug Delivery
March 15, 2018 08:30 ET
|
NetworkNewsWire
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial...
NetworkNewsAudio Covers New Patent Application of NeutriSci International Inc. (TXS-V:NU) (OTCQB:NRXCF)
March 05, 2018 08:30 ET
|
NetworkNewsWire
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for business, today announces the audio version of a...